News | Prostate Cancer | April 01, 2016

Augmenix Announces Publication of SpaceOAR Hydrogel Pivotal Clinical Study Results

Study demonstrates safety, excellent patient tolerance and improved patient outcomes in men undergoing prostate cancer radiotherapy

Augmenix, SpaceOAR System U.S. Clinical Trial, results, Urology Practice, prostate cancer, radiotherapy

April 1, 2016 — Augmenix Inc. announced the publication of the SpaceOAR System U.S. Clinical Trial results of the application technique and impact on prostate intensity modulated radiation therapy (IMRT).

Designed to act as a temporary spacer, the absorbable hydrogel pushes the rectum away from the prostate and reduces rectal radiation injury in men undergoing prostate cancer radiotherapy.

Published in the March issue of Urology Practice, an official journal of the American Urological Association (AUA), the paper describes outcomes in a randomized, controlled Level 1 clinical trial evaluating IMRT in prostate cancer patients with (SpaceOAR) and without (control) the prostate-rectum spacing hydrogel.

“The simple concept of an absorbable spacer improving prostate radiotherapy outcomes makes so much sense,” said Lawrence I. Karsh, M.D., director of research and attending urologist, The Urology Center of Colorado and a study investigator. “I insist on the best care for my patients, and knowing this tool is now available increases my confidence in achieving excellent radiotherapy outcomes.”

Between 2010 and 2013, 222 patients with stage T1 or T2 prostate cancer were enrolled in 20 centers across the United States. Either local, monitored or general anesthesia was used in an outpatient procedure to implant the hydrogel spacer. Patient tolerance of the spacer implantation procedure was deemed excellent, with only 10 percent of the SpaceOAR patients experiencing mild transient effects (e.g. transient perineal discomfort). The hydrogel spacer increased the prostate-rectum space by an average of 11mm (1.6 to 12.6mm), resulting in a significantly reduced radiation dose to the rectum with no signs of altering the prostate dose or increasing dose elsewhere. Median rectal (v70) radiation dose was decreased by 78 percent in SpaceOAR patients relative to control (p<0.0001).

As anticipated, the reduced rectal radiation improved outcomes. Patients in the SpaceOAR group experienced 76 percent less acute rectal pain events, a 71 percent reduction in the incidence of late rectal toxicity, and significant reductions in late rectal toxicity severity. In addition, patients in the SpaceOAR group experienced lower rates of decline in bowel quality of life.

The hydrogel spacer was absorbed when evaluated 12 months after implantation and there were no implant infections, rectal wall complications or other issues related to the implant.

The device received clearance from the U.S. Food and Drug Administration (FDA) in April 2015. Augmenix will showcase the SpaceOAR System at the 111th AUA Annual Meeting, taking place May 6 - 10 in San Diego.

For more information: www.augmenix.com

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...